Want to see GB:IBAI full AI Analyst Report?
Top Page
IQ-AI
(LSE:IBAI)
Select Model
Select Model
Rating:44Neutral
Price Target:
0.62 p
▼(-12.00% Downside)
Action:Reiterated
Date:09/15/26
The score is held down primarily by ongoing net losses and a weakened equity base despite improving revenue and a positive 2025 cash-flow inflection. Technicals add pressure with the stock trading below key moving averages, while valuation remains challenged due to a negative P/E and no stated dividend yield.
Positive Factors
Revenue Growth
Steady revenue expansion indicates continuing demand for the company’s products or services and provides a foundation for operating leverage. If growth persists, the larger revenue base could help spread fixed costs and support eventual progress toward sustainable profitability.
Negative Factors
Persistent Net Losses
Large ongoing losses show that revenue growth and strong gross margins have not yet translated into sustainable earnings. Continued losses can consume financial resources, constrain reinvestment, and make the company more dependent on future improvements in operating efficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Steady revenue expansion indicates continuing demand for the company’s products or services and provides a foundation for operating leverage. If growth persists, the larger revenue base could help spread fixed costs and support eventual progress toward sustainable profitability.
Read all positive factors
IQ-AI (IBAI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£1.73M
Dividend Yield5.85%
Average Volume (3M)373.31K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth15.80%
EPS Growth-66.67%
CountryUK
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding246,709,800
10 Day Avg. Volume269,516
30 Day Avg. Volume373,312
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)8.72
Price to Sales (P/S)2.60
P/FCF Ratio27.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IQ-AI Business Overview & Revenue Model
Company Description
Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier, Jersey, specializes in medical imaging diagnostics and clinical patient care. The company extends its services across the United Kingdom, Switzerland, the European Union, ...
How the Company Makes Money
null...
IQ-AI Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
45
Neutral
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 810.42K | 788.15K | 750.11K | 609.39K | 535.89K | 521.07K |
| Gross Profit | 661.16K | 646.11K | 687.87K | 482.35K | 534.10K | 504.02K |
| EBITDA | 121.90K | -65.95K | -272.63K | -498.55K | -360.28K | -356.87K |
| Net Income | -237.44K | -400.94K | -327.10K | -623.82K | -522.31K | -511.77K |
Balance Sheet | ||||||
| Total Assets | 1.18M | 1.01M | 929.67K | 720.74K | 1.27M | 1.58M |
| Cash, Cash Equivalents and Short-Term Investments | 49.38K | 112.61K | 53.50K | 138.75K | 313.99K | 728.59K |
| Total Debt | 177.45K | 172.32K | 0.00 | 0.00 | 62.20K | 55.41K |
| Total Liabilities | 875.04K | 778.82K | 627.14K | 625.81K | 560.51K | 392.79K |
| Stockholders Equity | 307.72K | 235.30K | 302.53K | 94.92K | 707.07K | 1.19M |
Cash Flow | ||||||
| Free Cash Flow | 153.64K | 74.34K | -136.16K | -175.23K | -414.60K | -345.32K |
| Operating Cash Flow | 153.65K | 74.34K | -136.16K | -96.83K | -374.67K | -288.76K |
| Investing Cash Flow | -176.62K | -255.53K | -308.98K | -78.41K | -39.93K | -56.56K |
| Financing Cash Flow | 0.00 | 240.30K | 359.89K | 0.00 | 0.00 | 595.00K |
IQ-AI Technical Analysis
Negative
0.70
Price Trends
0.67
Negative
0.65
Negative
0.65
Negative
Market Momentum
<0.01
Positive
43.25
Neutral
17.76
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IBAI, the sentiment is Negative. The current price of 0.7 is below the 20-day moving average (MA) of 0.71, above the 50-day MA of 0.67, and above the 200-day MA of 0.65, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 43.25 is Neutral, neither overbought nor oversold. The STOCH value of 17.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IBAI.
IQ-AI Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £16.42M | -3.83 | -16.18% | ― | 13.04% | 15.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £20.87M | -1.17 | -1044.57% | ― | 65.60% | 74.84% | |
44 Neutral | £1.73M | -4.88 | -87.45% | 5.85% | 15.80% | -66.67% | |
44 Neutral | £15.11M | -7.31 | -62.89% | ― | -9.11% | 18.91% | |
40 Underperform | £38.04M | -0.33 | -631.25% | ― | ― | ― | |
38 Underperform | £15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:IBAI
IQ-AI
0.64
<0.01
0.79%
GB:COG
Cambridge Cognition Holdings
28.00
-10.00
-26.32%
GB:GDR
Genedrive
1.28
0.78
158.10%
GB:IXI
IXICO plc
7.50
-4.00
-34.78%
GB:OBD
Oxford BioDynamics
0.12
-0.34
-74.44%
GB:RENX
Renalytix
6.40
-2.58
-28.73%
IQ-AI Corporate Events
Business Operations and StrategyProduct-Related Announcements
Imaging Biometrics Wins Key Health System Deal for Brain Tumor Imaging Software
Positive
Sep 15, 2026
Imaging Biometrics Limited has secured an annual subscription agreement with a major regional health system for its U.S. subsidiary’s quantitative neuro-oncology imaging software suite, including IB Neuro, IB Delta T1, and IB FTBx. The deal ...
Business Operations and Strategy
Imaging Biometrics Wins Major U.S. Hospital Deal for Brain Tumour Software
Positive
Aug 28, 2026
Imaging Biometrics’ U.S. subsidiary has secured an annual subscription from a major Midwest academic medical centre for IB Clinic, its automated brain tumour imaging platform. The deal will contribute fully to recurring revenue in 2027 and a...
Business Operations and StrategyFinancial Disclosures
Imaging Biometrics Returns to Profit as Neuro-Oncology Platform Gains Traction
Positive
Jul 29, 2026
Imaging Biometrics Limited reported a return to profitability in the first half of 2026, as revenue rose 6% to £416,270 and tighter cost control turned a prior operating loss into an £88,678 operating profit. The performance reflects a s...
Business Operations and StrategyRegulatory Filings and ComplianceStock Split
Imaging Biometrics Confirms Completion of Share Sub-Division
Positive
Jul 14, 2026
Imaging Biometrics Limited has completed a share sub-division, resulting in 246,709,789 ordinary shares with a nominal value of £0.005, following approval by the Jersey Financial Services Commission. The move formalises changes to the company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.